Exscientia (NASDAQ:EXAI) Reaches New 52-Week Low at $3.83

Exscientia plc (NASDAQ:EXAI)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $3.83 and last traded at $4.22, with a volume of 817217 shares traded. The stock had previously closed at $4.64.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EXAI. TD Cowen initiated coverage on Exscientia in a report on Tuesday, July 9th. They issued a “buy” rating on the stock. Barclays cut their price target on Exscientia from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Monday, July 29th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $7.00 price objective on shares of Exscientia in a research note on Monday, April 22nd.

Exscientia Stock Down 8.2 %

The company has a debt-to-equity ratio of 0.05, a current ratio of 6.30 and a quick ratio of 6.30. The firm has a 50-day simple moving average of $5.27 and a two-hundred day simple moving average of $5.46. The company has a market cap of $514.98 million, a PE ratio of -3.25 and a beta of 0.85.

Exscientia (NASDAQ:EXAI) last announced its earnings results on Tuesday, May 21st. The company reported ($0.21) earnings per share for the quarter. Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. The firm had revenue of $6.70 million during the quarter. Research analysts anticipate that Exscientia plc will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exscientia

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its stake in shares of Exscientia by 112.1% during the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after acquiring an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Exscientia by 359.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock worth $34,000 after purchasing an additional 4,104 shares during the period. Walled Lake Planning & Wealth Management LLC acquired a new position in shares of Exscientia in the 4th quarter valued at $64,000. New Republic Capital LLC purchased a new stake in shares of Exscientia during the 4th quarter valued at $128,000. Finally, Private Advisor Group LLC increased its holdings in shares of Exscientia by 114.3% during the 4th quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock worth $144,000 after buying an additional 12,000 shares during the last quarter. Institutional investors and hedge funds own 41.58% of the company’s stock.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.